BioCity’s SC0062 gains NMPA breakthrough therapy designation
The CDE of China's NMPA has granted BioCity's endothelin receptor type A (ETA) antagonist, SC0062, a second BTD.
The CDE of China's NMPA has granted BioCity's endothelin receptor type A (ETA) antagonist, SC0062, a second BTD.
What's Your Reaction?
